American Heart Journal
Volume 157, Issue 3 , Page e13 , March 2009

Role of aldosterone receptor antagonist eplerenone in aortic stenosis

References 

  1. Stewart RA, Kerr AJ, Cowan BR, et al. A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate-severe aortic stenosis. Am Heart J. 2008;156:348–355
  2. Tsybouleva N, Zhang L, Chen S, et al. Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation. 2004;109:1284–1291
  3. de Resende MM, Kriegel AJ, Greene AS. Combined effects of low-dose spironolactone and captopril therapy in a rat model of genetic hypertrophic cardiomyopathy. J Cardiovasc Pharmacol. 2006;48:265–273
  4. Chai W, Hoedemaekers Y, van Schaik RH, et al. Cardiac aldosterone in subjects with hypertrophic cardiomyopathy. J Renin Angiotensin Aldosterone Syst. 2006;7:225–230
  5. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–717
  6. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–1321
  7. Ramaraj R, Sorrell VL. Degenerative aortic stenosis. BMJ. 2008;336:550–555
  8. Moura LM, Ramos SF, Zamorano JL, et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol. 2007;49:554–561

PII: S0002-8703(08)00914-9

doi: 10.1016/j.ahj.2008.10.022

American Heart Journal
Volume 157, Issue 3 , Page e13 , March 2009

Article Tools